ZymoGenetics, Inc.
_________________________________________________________________________________
ZymoGenetics, Inc. Financial Snapshot
Operating Performance
Fast Facts
1201 Eastlake Avenue East, Seattle, The company reported revenues of US$136.97 million
Headquarters Address
98102,United States of America during 2009, with a CAGR of 33.67% during 2005–
2009. Its revenue grew at an annual rate of 85.12%
Telephone + 1 206 4426600
over the previous fiscal year. In 2009, the company
recorded an operating margin of -23.40%, as against -
Fax + 1 206 4426608 160.29% in 2008.
Website www.zymogenetics.com
Revenue and Margins
Ticker Symbol, Stock Exchange ZGEN, NASDAQ
Number of Employees 323
Fiscal Year End December
Revenue (in US$ million) 136.97
SWOT Analysis
Strengths Weaknesses Return on Equity
Collaborations Increasing Current Liabilities The company recorded a return on equity (ROE) of
0.00% for 2009, as compared to its peers, Amgen Inc.
First Commercial Product - (Ticker: AMGN), Biogen Idec Inc. (Ticker: BIIB) and
Lack of Direct Selling Operations King Pharmaceuticals, Inc. (Ticker: KG), which
RECOTHROM
recorded ROEs of 20.32%, 15.59% and 3.88%
Focused R&D Third-party Dependence respectively. The company reported an operating
margin of -23.40% in 2009.
Strong Revenue Growth Weak Operational Performance
Return on Equity
Opportunities Threats
Licensing of Non-Core Assets Counterfeit Drugs
Pipeline Products Uncertain R&D Outcomes
Restructuring
Liquidity Position
The company reported a current ratio of 1.79 in 2009,
as compared to its peers, Amgen Inc., Biogen Idec
Inc. and King Pharmaceuticals, Inc., which recorded
current ratios of 4.89, 3.47 and 2.27 respectively. As
of December 2009, the company recorded cash and
short-term investments of worth US$174.13 million,
against US$0.93 million current debt. The company
reported a debt to equity ratio of -23.62 in 2009 as
compared to its peers, Amgen Inc., Biogen Idec Inc.
and King Pharmaceuticals, Inc., which recorded debt
to equity ratios of 0.47, 0.18 and 0.18 respectively.
___________________________________________________________________________________________
ZymoGenetics, Inc. - SWOT Profile Page 1
ZymoGenetics, Inc.
_________________________________________________________________________________
TABLE OF CONTENTS
1 Business Analysis ................................................................................................................................... 5
1.1 Company Overview ................................................................................................................................................5
1.2 Business Description ..............................................................................................................................................5
1.3 Major Products and Services .................................................................................................................................6
2 Analysis of Key Performance Indicators ............................................................................................... 7
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
2.2 Key Financial Performance Indicators .................................................................................................................10
2.2.1 Revenue and Operating Profit .........................................................................................................................10
2.2.2 Asset, Liabilities and Capex .............................................................................................................................11
2.2.3 Operational Efficiency ......................................................................................................................................12
2.2.4 Solvency ..........................................................................................................................................................13
2.3 Competitive Benchmarking ..................................................................................................................................14
2.3.1 Market Capitalization .......................................................................................................................................14
2.3.2 Efficiency ..........................................................................................................................................................15
2.3.3 Capital Expenditure..........................................................................................................................................16
2.3.4 Turnover – Inventory and Asset .......................................................................................................................17
2.3.5 Liquidity ............................................................................................................................................................18
3 Mergers & Acquisitions and Partnerships ........................................................................................... 19
3.1 M&A and Partnerships Strategy ...........................................................................................................................19
4 Recent Developments ........................................................................................................................... 20
5 SWOT Analysis ...................................................................................................................................... 22
5.1 SWOT Analysis - Overview ..................................................................................................................................22
5.2 Strengths ..............................................................................................................................................................22
5.3 Weaknesses .........................................................................................................................................................23
5.4 Opportunities ........................................................................................................................................................23
5.5 Threats .................................................................................................................................................................24
6 ZymoGenetics, Inc. - Company Statement........................................................................................... 25
7 History .................................................................................................................................................... 26
8 ZymoGenetics, Inc. - Key Employees................................................................................................... 28
9 Key Employee Biographies................................................................................................................... 29
10 Appendix ......................................................................................